linkedin

Press Releases

Samsung BIO Insight

BioProcess International 2022 | Samsung Biologics unveils new development platforms to offer differentiated services

SamsungBIologics_BPI2022_Thumbnail.jpg
 
 

Samsung Biologics introduced two new development technology platforms at BioProcess International 2022 between September 27-30 in Boston. The conference is the largest bioprocessing event, inviting over 1,800 experts to discuss how to accelerate promising biologics, cell and gene therapies towards commercial success. 

 

 

Launching platforms S-DUALTM and DEVELOPICKTM

 

At this year’s event, Samsung Biologics showcased its strength in the CDO business by introducing new proprietary development technology platforms: S-DUAL™ and DEVELOPICK™.

 

SamsungBIologics_BPI2022_1.jpgSamsungBIologics_BPI2022_2.jpg

SamsungBIologics_BPI2022_3.jpg

SamsungBIologics_BPI2022_4.jpg

SamsungBIologics_BPI2022_5.jpg

 

S-DUAL™ is a high-yield bispecific antibody platform with a 99% chain-pairing success rate. Its unique asymmetrical structure reduces the risk of mispairing and ensures high binding affinity among chains to produce high titer and purity for optimized manufacturability. Bispecific antibodies are capable of targeting two different antigens at once, improving treatment potential. According to the research and consulting firm Roots Analysis, the global bispecific antibody market is expected to grow at an annual rate of 34% to reach 9.6 billion USD by 2030. 

 

DEVELOPICK™ is a rapid developability assessment platform that systematically screens molecules at an early stage to identify candidates with the best potential for advancement to Investigational New Drug. The assessment platform enables clients to conduct a robust risk assessment for unsorted drug candidates within a month. By utilizing DEVELOPICK™, Samsung Biologics can provide early insight and selection guidance to save time and cost, and ultimately maximize efficiency.

 

 

Promoting Strengths of Differentiated CDO Services and Bolstering Networking

 

SamsungBIologics_BPI2022_12.jpg 

 

On September 30, Wonjun Yang, Lead Scientist for Antibody-Based Research at Samsung Biologics, shared his insights and new approaches in bispecific antibody development.

 

Samsung Biologics also held a total of four poster sessions to promote DEVELOPICK and its MSAT (Manufacturing Science and Technology) capabilities during the three-day event to showcase the company’s competency in the contract development business.

 

SamsungBIologics_BPI2022_6.jpg

SamsungBIologics_BPI2022_7.jpg

SamsungBIologics_BPI2022_8.jpg

  

Solidifying Global Foothold as a Partner for Successful Development of New Drugs

 

SamsungBIologics_BPI2022_10.jpg 

 

Samsung Biologics has won over 100 projects since it first launched its CDO business in 2018. It offers end-to-end, one-stop services, from cell line development to integrated manufacturing from clinical to commercial, enabling cost and time reduction for development.

 

Samsung Biologics continues to strengthen its foothold in the global contract development market, by opening an R&D Center in San Francisco in 2020, launching its proprietary cell line, S-CHOice® in 2021, and the ‘S-DUALTM’ and ‘DEVELOPICKTM’ this year. Samsung Biologics will continue innovating for the successful development of new drugs and the production of high-quality biopharmaceuticals for clients.

 

 

 

Related Contents

 

Press Release Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022 

Samsung BIO Insight The Value of Reducing Your Drug Development Timeline

Samsung BIO Insight The Journey to Your Success | Explore Samsung Biologics' CDO Strengths

 

SamsungBIologics_BPI2022_Thumbnail.jpg
 
 

Samsung Biologics introduced two new development technology platforms at BioProcess International 2022 between September 27-30 in Boston. The conference is the largest bioprocessing event, inviting over 1,800 experts to discuss how to accelerate promising biologics, cell and gene therapies towards commercial success. 

 

 

Launching platforms S-DUALTM and DEVELOPICKTM

 

At this year’s event, Samsung Biologics showcased its strength in the CDO business by introducing new proprietary development technology platforms: S-DUAL™ and DEVELOPICK™.

 

SamsungBIologics_BPI2022_1.jpgSamsungBIologics_BPI2022_2.jpg

SamsungBIologics_BPI2022_3.jpg

SamsungBIologics_BPI2022_4.jpg

SamsungBIologics_BPI2022_5.jpg

 

S-DUAL™ is a high-yield bispecific antibody platform with a 99% chain-pairing success rate. Its unique asymmetrical structure reduces the risk of mispairing and ensures high binding affinity among chains to produce high titer and purity for optimized manufacturability. Bispecific antibodies are capable of targeting two different antigens at once, improving treatment potential. According to the research and consulting firm Roots Analysis, the global bispecific antibody market is expected to grow at an annual rate of 34% to reach 9.6 billion USD by 2030. 

 

DEVELOPICK™ is a rapid developability assessment platform that systematically screens molecules at an early stage to identify candidates with the best potential for advancement to Investigational New Drug. The assessment platform enables clients to conduct a robust risk assessment for unsorted drug candidates within a month. By utilizing DEVELOPICK™, Samsung Biologics can provide early insight and selection guidance to save time and cost, and ultimately maximize efficiency.

 

 

Promoting Strengths of Differentiated CDO Services and Bolstering Networking

 

SamsungBIologics_BPI2022_12.jpg 

 

On September 30, Wonjun Yang, Lead Scientist for Antibody-Based Research at Samsung Biologics, shared his insights and new approaches in bispecific antibody development.

 

Samsung Biologics also held a total of four poster sessions to promote DEVELOPICK and its MSAT (Manufacturing Science and Technology) capabilities during the three-day event to showcase the company’s competency in the contract development business.

 

SamsungBIologics_BPI2022_6.jpg

SamsungBIologics_BPI2022_7.jpg

SamsungBIologics_BPI2022_8.jpg

  

Solidifying Global Foothold as a Partner for Successful Development of New Drugs

 

SamsungBIologics_BPI2022_10.jpg 

 

Samsung Biologics has won over 100 projects since it first launched its CDO business in 2018. It offers end-to-end, one-stop services, from cell line development to integrated manufacturing from clinical to commercial, enabling cost and time reduction for development.

 

Samsung Biologics continues to strengthen its foothold in the global contract development market, by opening an R&D Center in San Francisco in 2020, launching its proprietary cell line, S-CHOice® in 2021, and the ‘S-DUALTM’ and ‘DEVELOPICKTM’ this year. Samsung Biologics will continue innovating for the successful development of new drugs and the production of high-quality biopharmaceuticals for clients.

 

 

 

Related Contents

 

Press Release Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022 

Samsung BIO Insight The Value of Reducing Your Drug Development Timeline

Samsung BIO Insight The Journey to Your Success | Explore Samsung Biologics' CDO Strengths

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved